Диссертация (1140614), страница 15
Текст из файла (страница 15)
Predictive factors forconcurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrencein case of superficial venous thrombosis. The OPTIMEV study // Thromb. Haemost. –2011. – Vol.105 (1) – P.31-39.92.Gallardo Jiminez P., Guijarro Merino R., Vallejo Herrera V. et al.Assessment of venous thromboembolism risk in hospitalized medical patients.Concordance between PRETEMED guide and the recommendations of the viiiconference of the American College of Chest Physicians // Med.
Clin. (Barc). – 2012. –Vol.139 (11). – P.467-47.93.Garcia D.A., Crowther M.A. Reversal of warfarin: case-based practicerecommendations // Circulation. – 2012. – Vol.125 (23). – P.2944–2947.94.Giugliano R.P., Ruff C.T., Braunwald E. et al. Edoxaban versuswarfarin in patients with atrial fibrillation // N Engl. J. Med. – 2013. – Vol.369 (22). –P. 2093–2104.95.Goldhaber S., Tapson V.F.
DVT Free Steering Commit-tee. AProspective Registry of 5, 451 patients with ultra-sound-confirmed deep veinthrombosis // Am. J. Card. - 2009. – Vol.93(2). – P.259–262.10096.GoldhaberS.Z.Venous thromboembolism:epidemiologyandmagnitude of the problem // Best Pract. Res. Clin. Haematol. – 2012. – Vol.25 (3). –P.235-242.97.HaasS.,HohmannV.,BramlageP.Preventionof venous thromboembolism using enoxaparin in day surgery: results of the SMARTnoninterventional study // Clin. Appl. Thromb.
Hemost. – 2012. – Vol.18(3). – P.265271.98.Hancock H.S., Wang M., Gist K.M. et al. Cardiac findings and long-term thromboembolic outcomes following pulmonary embolism in children: a combinedretrospective-prospective inception cohort study // Cardiol. Young. - 2013. – Vol.23(3). –P.344-352.99.Harder S., Graff J. Novel oral anticoagulants: clinical pharmacology,indications and practical considerations // Eur.
J. Clin. Pharmacol. – 2013. - Apr. 26.[Epub ahead of print].100.Harenberg J., Marx S., Erdle S., Kramer R. Determination of theanticoagulant effects of new oral anticoagulants: an unmet need // Expert. Rev.Hematol. – 2012. – Vol.5 (1). – P.107-113.101.Harper P., Young L., Merriman E. Bleeding risk with dabigatran in thefrail elderly // N Engl.
J. Med. – 2012. – Vol.366 (9). – P.864–866.102.Harrington A.R., Armstrong E.P., Nolan P.E., Malone D.C. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention inatrial fibrillation // Stroke. – 2013. – Vol.44. – P.1676–1681.103.HaschkeM.Clinicalpharmacologicalaspectsofneworalanticoagulants // Ther. Umsch. – 2012. – Vol.69 (11).
– P.657-660.104.Healey J.S., Eikelboom J., Douketis J. et al. Periprocedural bleeding andthromboembolic events with dabigatran compared with warfarin: results from theRandomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomizedtrial // Circulation. – 2012. – Vol.126 (3). - P.343–348.101105.Hickey K. Anticoagulation management in clinical practice: preventingstroke in patients with atrial fibrillation // Heart Lung. - 2012. – Vol.41(2).
– P.146–156.106.Hillman M.A., Wilke R.A., Yale S.H. at al. A prospective, randomizedpilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinicaldata // Clinical Medicine Research. – 2005. – Vol.3. – P.137-145.107.Hong D., Song S.W. Pulmonary embolism caused by popliteal venousaneurysm // Korean J. Thorac. Cardiovasc. Surg.
– 2013. – Vol.46 (1). – P.76-79.108.HowardL.S.,HughesR.J.NICEguideline:managementof venous thromboembolic diseases and role of thrombophilia testing // Thorax. – 2013.– Vol.68 (4). – P.391-393.109.Hull R.D., Schellonq S.M., Tapson V.F. et al. Exctended-durationthromboprophylaxis in acutely ill medical patients with reduced morbidity:methodology for the EXCLAIM study //J.
Thrombolysis. – 2006. – Vol.22 (1). – P.3138.110.Ilic M., Kikelj D., Ilac J. Multitarget antithrombotic drugs // Curr. Top.Med. Chem. – 2011. – Vol.11 (22). – P.2834-2848.111.Iwatsuki Y., Sato T., Moritani Y. et al.Biochemical andpharmacological profile of darexaban, an oral direct factor Xa inhibitor // Eur. J.Pharmacol. – 2011. – Vol.673 (1-3). – P.49-55.112.Jankowski M., Undas A., Kaczmarek P., Butenas S. Activated factor XIand tissue factor in chronic obstructive pulmonary disease: links with inflammation andthrombin generation // Thromb.
Res. – 2011. – Vol.127 (3). – P.242-246.113.Kadokura T., Taniuchi Y., Inoue H. et al. Effect of food on thepharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanesesubjects // Int. J. Clin. Pharmacol. Ther. - 2013. – Vol.51 (3). – P.200-206.114.Kadusevicius E., Kildonaviciute G., Varanaviciene B., Jankauskiene D.Low-molecular-weight heparins: pharmacoeconomic decision modeling based on metaanalysis data // Int. J. Technol. Assess Health Care. - 2010.
– Vol.26 (3). – P.272-279.102115.Kalus J.S. Antithrombotic alternatives for stroke prevention in atrialfibrillation: critical differences and remaining questions // Drugs Context. - 2013. –Vol.2013. – P.212251.116.Kangelaris K., Bent S., Nussbaum R. at al. Genetic testing beforeanticoagulation? A systematic review of pharmacogenetic dosing of warfarin // J.General Internal Medicine. – 2009. – Vol.24. – P.656-664.117.Kociol R.D., Hammill B.G., Hernandez A.F. et al.
Pharmacologicprophylaxis for venous thromboembolism and 30-day outcomes among older patientshospitalized with heart failure: an analysis from the ADHERE national registry linkedto Medicare claims // Clin. Cardiol. – 2011. – Vol.34 (11). – P.682-688.118.Kwok C.S., Pradhan S., Yeong J.K., Loke Y.K. Relative effects of twodifferent enoxaparin regimens as comparators against newer oral anticoagulants: metaanalysis and adjusted indirect comparison // Chest. – 2013. - Mar 21.
[Epub ahead ofprint].119.Lang I.M., Simonneau G., Pepke-Zaba J.W. et al. Factors associatedwith diagnosis and operability of chronic thromboembolic pulmonary hypertension. Acase-control study // Thromb. Haemost. – 2013. - May 16. Epub ahead of print.120.Langley M.R., Booker J.K., Evans J.P. at al. Validation of clinicaltesting for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assaysand warfarin-dosing algorithms // J. Molecular Diagnostics.
- 2009. – Vol. 11. – P.216225.121.Languasco A., Galante M., Marin J. et al. Adherence to local guidelinesfor venous thromboprophylaxis: a cross-sectional study of medical inpatients inArgentina // Thromb J. – 2011. – Vol.15 (9). – P.18.122.Larock A.S., Mullier F., Laloux P. et al. The mirages of thenew oral anticoagulants // J. Pharm. Belg. - 2014. – Vol.11. – P.38-41.123.Lauritzen B., Hedner U., Johansen P.B. et al. Recombinant humanfactor VIIa and a factor VIIa-analogue reduces heparin and low molecular weightheparin (LMWH)-induced bleeding in rats // J.
Thromb. Haemost. – 2008. – Vol.6 (5).– P.804–811.103124.Lee A.Y., Bauersachs R., Janas M.S. et al. CATCH: a randomisedclinical trial comparing long-term tinzaparin versus warfarin for treatment ofacute venous thromboembolism in cancer patients // BMC Cancer. – 2013. – Vol.13(1).– P.284.125.Lee C.J., Ansell J.E. Direct thrombin inhibitors // Br. J. Clin.Pharmacol.
– 2011. – Vol.72 (4). – P.581-592.126.Lenchus J.D. Strategies for venous thromboembolism prophylaxisprograms // Postgrad. Med. - 2011. – Vol.123 (6). – P.91-101.127.Lip G.Y, Nieuwlaat R., Pisters R. et al. Refining clinical riskstratification for predicting stroke and thromboembolism in atrial fibrillation using anovel risk factor-based approach: the Euro Heart Survey on atrial fibrillation // Chest. 2010. – Vol.137. –P.263–272.128.Lu G., DeGuzman F.R., Hollenbach S.J.
et al. A specific antidote forreversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa //Nat. Med. – 2013. – Vol.19 (4). – P.446–451.129.MahmudT.Pulmonaryembolism,thrombocytopenia,andantiphospholipid syndrome // J. Ayub. Med. Coll. Abbottabad.
– 2011. – Vol.23 (4). –P.138-141.130.Mamchur S.E., Mamchur I.N., Khomenko E.A. et al. Catheter ablationfor atrial fibrillation after an unsuccessful surgical ablation and biological prostheticmitral valve replacement: A pilot study // J. Chin. Med. Assoc. – 2014. - Aug 7. [Epubahead of print]131.Mani H., Kasper A., Lindhoff-Last E. Measuring the anticoagulanteffects of target specific oral anticoagulants-reasons, methods and current limitations //J.
Thromb. Thrombolysis. – 2013. – Vol.36 (2). – P.187–194.132.Mani H., Rohde G., Stratmann G. et al. Accurate determination ofrivaroxaban levels requires different calibrator sets but not addition of antithrombin //Thromb. Haemost. - 2012. – Vol.108 (1). – P.191–198.104133.Mani H., Lindhoff-Last E. New oral anticoagulants in patients withnonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality oflife, and cost effectiveness // Drug Des. Devel.
Ther. - 2014. – Vol.8. – P.789-798.134.Marchena Yglesias P.J. New evidence in the secondary preventionof thromboembolic disease // Med. Clin. (Barc). – 2012. – Vol.139. Suppl. 2. – P.2430.135.Marcucci M., Smith C.T., Douketis J.D. et al. Patient-level comparedwith study-level meta-analyses demonstrate consistency of D-dimer as predictorof venous thromboembolic recurrences // J. Clin.
Epidemiol. – 2013. – Vol.66 (4). –P.415-425.136.Martinez-Murillo C., Aguilar-Arteaga M.L., Velasco-Ortega E. et al.Clinical guideline for diagnosis and treatment of the thromboembolic venous disease //Rev. Med. Inst. Mex. Seguro Soc. -2011. –Vol.49 (4). – P.437-449.137.Masopust J., Mali R., Valic M. Risk of venous thromboembolismduring treatment with antipsychotic agents // Psychiatry Clin. Neurosci. – 2012. –Vol.66 (7). – P.541-552.138.McCready R.A. Perioperative venous thromboembolic events (VTE):can we lower the risk ever further? // J. Surg. Res. - 2013.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
